| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Myeloperoxidase Antibody
MessageSendout, Mayo test code: MPO
Test Code
LAB5210321
Alias/See Also
ANCA (Antineutrophil Cytoplasmic Antibodies)
Anti-Myeloperoxidase Antibodies
Antibodies to Myeloperoxidase
Anticytoplasmic Autoantibodies
Antineutrophil Cytoplasmic Antibodies (ACPA)
Autoantibodies to Myeloperoxidase
Autoantibodies to Proteinase 3
Cytoplasmic Neutrophil Antibodies
Myeloperoxidase Antibodies (MPO)
Neutrophil Cytoplasmic Antibodies
Wegener's Granulomatosis
Perinuclear Antineutrophil Cytoplasmic Antibody (pANCA)
MPO
Anti-Myeloperoxidase Antibodies
Antibodies to Myeloperoxidase
Anticytoplasmic Autoantibodies
Antineutrophil Cytoplasmic Antibodies (ACPA)
Autoantibodies to Myeloperoxidase
Autoantibodies to Proteinase 3
Cytoplasmic Neutrophil Antibodies
Myeloperoxidase Antibodies (MPO)
Neutrophil Cytoplasmic Antibodies
Wegener's Granulomatosis
Perinuclear Antineutrophil Cytoplasmic Antibody (pANCA)
MPO
CPT Codes
83516
Preferred Specimen
0.5 mL serum from a gold serum gel tube
Minimum Volume
0.35 mL
Other Acceptable Specimens
Red tube
Instructions
Centrifuge and aliquot serum into a plastic vial.
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 21 days
Frozen 21 days
Frozen 21 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: OK
Gross lipemia: Reject
Gross icterus: OK
Methodology
Multiplex Flow Immunoassay
FDA Status
Approved
Setup Schedule
Monday through Saturday
Report Available
1-4 days
Limitations
Since it is not possible to distinguish between microscopic polyangiitis (MPA) and other causes of progressive renal failure or systemic illness (eg, Wegener granulomatosis, lupus nephritis, Goodpasture syndrome), this test should be employed in conjunction with other diagnostic tests in the initial evaluation of such patients. The recommended test in this setting is VASC / Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum, which includes myeloperoxidase (MPO) antibodies, proteinase 3 (PR3) antibodies and, if indicated, antineutrophil cytoplasmic antibodies (ANCA). The test for ANCA identifies 2 types of antibodies-cytoplasmic (cANCA), which are specific for PR3 and perinuclear (pANCA), which are specific for MPO.
The presence of MPO is quite specific for MPA (diagnostic specificity approaches 95%); but, it is recommended that positive results obtained by EIA be confirmed by another testing method. This is best accomplished by testing for pANCA, which confirms the positive MPO result and increases the diagnostic specificity for MPA to 97%.(3) Nevertheless, positive results for MPO have been reported in patients with systemic lupus erythematosus, Goodpasture syndrome, and Churg-Strauss syndrome. Therefore, clinicians must rule out these diagnoses to maximize the specificity and positive predictive value of the MPO test result.
While sequential measurements of MPO may be used to follow treatment response or to monitor disease activity in patients with MPA, results should not be exclusively relied upon to assess response to treatment or disease activity.
The presence of MPO is quite specific for MPA (diagnostic specificity approaches 95%); but, it is recommended that positive results obtained by EIA be confirmed by another testing method. This is best accomplished by testing for pANCA, which confirms the positive MPO result and increases the diagnostic specificity for MPA to 97%.(3) Nevertheless, positive results for MPO have been reported in patients with systemic lupus erythematosus, Goodpasture syndrome, and Churg-Strauss syndrome. Therefore, clinicians must rule out these diagnoses to maximize the specificity and positive predictive value of the MPO test result.
While sequential measurements of MPO may be used to follow treatment response or to monitor disease activity in patients with MPA, results should not be exclusively relied upon to assess response to treatment or disease activity.
Reference Range
Included with report
Clinical Significance
Evaluating patients suspected of having immune-mediated vasculitis, especially microscopic polyangiitis (MPA), when used in conjunction with other autoantibody tests (see Cautions)
May be useful to follow treatment response or to monitor disease activity in patients with MPA
May be useful to follow treatment response or to monitor disease activity in patients with MPA
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Myeloperoxidase Antibodies, IgG, Serum
